||||||||||ADA-011 / Adanate Enrollment open, Combination therapy, Monotherapy, Checkpoint inhibition, Metastases: A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jan 9, 2023 P1, N=90, Recruiting, Sponsor: Adanate, Inc Not yet recruiting --> Recruiting
||||||||||ADA-011 / Adanate New P1 trial, Combination therapy, Monotherapy, Checkpoint inhibition, Metastases: A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Nov 1, 2022 P1, N=90, Not yet recruiting, Sponsor: Adanate, Inc